JP2020504753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504753A5 JP2020504753A5 JP2019535368A JP2019535368A JP2020504753A5 JP 2020504753 A5 JP2020504753 A5 JP 2020504753A5 JP 2019535368 A JP2019535368 A JP 2019535368A JP 2019535368 A JP2019535368 A JP 2019535368A JP 2020504753 A5 JP2020504753 A5 JP 2020504753A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- sulfonamide
- indole
- fluoro
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, bromo, iodo Chemical group 0.000 claims description 490
- 125000003545 alkoxy group Chemical group 0.000 claims description 272
- 125000001153 fluoro group Chemical group F* 0.000 claims description 244
- 229910052739 hydrogen Inorganic materials 0.000 claims description 234
- 239000001257 hydrogen Substances 0.000 claims description 234
- 125000000217 alkyl group Chemical group 0.000 claims description 186
- 150000002431 hydrogen Chemical group 0.000 claims description 153
- 229910052736 halogen Chemical group 0.000 claims description 119
- 150000002367 halogens Chemical group 0.000 claims description 114
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 93
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 87
- 150000001875 compounds Chemical class 0.000 claims description 72
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 67
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 57
- 125000001424 substituent group Chemical group 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 51
- 125000003342 alkenyl group Chemical group 0.000 claims description 50
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
- 125000000304 alkynyl group Chemical group 0.000 claims description 46
- 125000001246 bromo group Chemical group Br* 0.000 claims description 43
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 39
- 229910052799 carbon Inorganic materials 0.000 claims description 35
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 35
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- 239000012453 solvate Substances 0.000 claims description 34
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 33
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 125000004076 pyridyl group Chemical group 0.000 claims description 30
- 239000013078 crystal Substances 0.000 claims description 29
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 28
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 28
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- ZRNSSRODJSSVEJ-UHFFFAOYSA-N 2-methylpentacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(C)C ZRNSSRODJSSVEJ-UHFFFAOYSA-N 0.000 claims description 15
- 208000016192 Demyelinating disease Diseases 0.000 claims description 15
- 206010012305 Demyelination Diseases 0.000 claims description 15
- NBVXSUQYWXRMNV-UHFFFAOYSA-N monofluoromethane Natural products FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 15
- 125000001544 thienyl group Chemical group 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 13
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
- 125000006595 (C1-C3) alkylsulfinyl group Chemical group 0.000 claims description 11
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims description 11
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 11
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 10
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 10
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 10
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 8
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 claims description 7
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 7
- 230000023105 myelination Effects 0.000 claims description 7
- FTNJQNQLEGKTGD-ZFJHNFROSA-N 1,3-benzodioxole Chemical group C1O[13C]=2[13CH]=[13CH][13CH]=[13CH][13C]=2O1 FTNJQNQLEGKTGD-ZFJHNFROSA-N 0.000 claims description 6
- PDQRQJVPEFGVRK-UHFFFAOYSA-N 2,1,3-benzothiadiazole Chemical compound C1=CC=CC2=NSN=C21 PDQRQJVPEFGVRK-UHFFFAOYSA-N 0.000 claims description 6
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 102000014461 Ataxins Human genes 0.000 claims description 6
- 108010078286 Ataxins Proteins 0.000 claims description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 6
- 150000001540 azides Chemical class 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 210000005013 brain tissue Anatomy 0.000 claims description 6
- 208000009885 central pontine myelinolysis Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
- 125000006005 fluoroethoxy group Chemical group 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 3
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000014644 Brain disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 3
- 206010010252 Concentric sclerosis Diseases 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 3
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 3
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims description 3
- 208000032274 Encephalopathy Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000003435 Optic Neuritis Diseases 0.000 claims description 3
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 208000021235 Schilder disease Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 3
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 230000009984 peri-natal effect Effects 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 230000000472 traumatic effect Effects 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 2
- 150000000183 1,3-benzoxazoles Chemical class 0.000 claims description 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 claims description 2
- XJVDIMLQFRPIMP-UHFFFAOYSA-N 3-methyl-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(C)OC(=O)C2=C1 XJVDIMLQFRPIMP-UHFFFAOYSA-N 0.000 claims description 2
- NBTPVYAEZALYIJ-UHFFFAOYSA-N 5-bromo-6-chloro-N-(4-chloro-2,5-difluorophenyl)-1H-indole-3-sulfonamide Chemical compound BrC=1C=C2C(=CNC2=CC=1Cl)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F NBTPVYAEZALYIJ-UHFFFAOYSA-N 0.000 claims description 2
- AYLDUKSYEVZYRT-UHFFFAOYSA-N 6-bromo-N-(2,4-difluorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(2,2-difluoro-1,3-benzodioxol-4-yl)-6-methylsulfonyl-1H-indole-3-sulfonamide Chemical compound BrC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=C(C=C(C=C2)F)F.FC2(OC1=C(O2)C=CC=C1NS(=O)(=O)C1=CNC2=CC(=CC=C12)S(=O)(=O)C)F AYLDUKSYEVZYRT-UHFFFAOYSA-N 0.000 claims description 2
- UPKPNIFYJDQRBL-UHFFFAOYSA-N 6-bromo-N-(4-cyanophenyl)-1H-indole-3-sulfonamide 6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-(2,2-difluoroethoxy)-1H-indole-3-sulfonamide Chemical compound BrC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=C(C=C1)C#N.ClC1=CC=C2C(=CNC2=C1OCC(F)F)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F UPKPNIFYJDQRBL-UHFFFAOYSA-N 0.000 claims description 2
- RCVMTDVQQGOWNZ-UHFFFAOYSA-N 6-chloro-N-(2,4,5-trifluorophenyl)-1H-indole-3-sulfonamide N-[4-(difluoromethoxy)-2,5-difluorophenyl]-6-methylsulfinyl-1H-indole-3-sulfonamide Chemical compound Fc1cc(F)c(NS(=O)(=O)c2c[nH]c3cc(Cl)ccc23)cc1F.CS(=O)c1ccc2c(c[nH]c2c1)S(=O)(=O)Nc1cc(F)c(OC(F)F)cc1F RCVMTDVQQGOWNZ-UHFFFAOYSA-N 0.000 claims description 2
- JUGTZHMQUVPXOS-UHFFFAOYSA-N 6-chloro-N-(2,5-difluoro-4-methylphenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-chloro-2,5-difluorophenyl)-8-oxo-1,9-dihydropyrrolo[3,2-h]quinoline-3-sulfonamide Chemical compound Cc1cc(F)c(NS(=O)(=O)c2c[nH]c3nc(Cl)ccc23)cc1F.Fc1cc(NS(=O)(=O)c2c[nH]c3c2ccc2ccc(=O)[nH]c32)c(F)cc1Cl JUGTZHMQUVPXOS-UHFFFAOYSA-N 0.000 claims description 2
- WEJKSGPVXNCTFP-UHFFFAOYSA-N 6-chloro-N-(4,6-dichloropyridin-2-yl)-1H-indole-3-sulfonamide N-(2,2-difluoro-1,3-benzodioxol-4-yl)-5-iodo-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=CC(=C1)Cl)Cl.FC1(OC2=C(O1)C=CC=C2NS(=O)(=O)C2=CNC1=NC=C(C=C12)I)F WEJKSGPVXNCTFP-UHFFFAOYSA-N 0.000 claims description 2
- KMAGLOZKFZXCKJ-UHFFFAOYSA-N 6-chloro-N-(4-chloro-2,5-difluorophenyl)-1H-indole-3-sulfonamide 6-chloro-N-[4-(difluoromethoxy)-2,5-difluorophenyl]-1H-indole-3-sulfonamide Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C(=C1)F)OC(F)F)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F KMAGLOZKFZXCKJ-UHFFFAOYSA-N 0.000 claims description 2
- PCPSTIWCSWWMHI-UHFFFAOYSA-N 6-chloro-N-(4-chloro-2,5-difluorophenyl)-7-methylsulfinyl-1H-indole-3-sulfonamide 6-chloro-N-(3,6-difluoro-5-propan-2-ylpyridin-2-yl)-1H-indole-3-sulfonamide Chemical compound CC(C)c1cc(F)c(NS(=O)(=O)c2c[nH]c3cc(Cl)ccc23)nc1F.CS(=O)c1c(Cl)ccc2c(c[nH]c12)S(=O)(=O)Nc1cc(F)c(Cl)cc1F PCPSTIWCSWWMHI-UHFFFAOYSA-N 0.000 claims description 2
- UONNBAGIVWWWEA-UHFFFAOYSA-N 6-chloro-N-(6-cyano-2,2-difluoro-1,3-benzodioxol-4-yl)-1H-indole-3-sulfonamide N-(4-chloro-2,5-difluorophenyl)-2-fluoro-6-methoxy-1H-indole-3-sulfonamide Chemical compound ClC1=CC(=C(C=C1F)NS(=O)(=O)C1=C(NC2=CC(=CC=C12)OC)F)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC(=CC=2OC(OC21)(F)F)C#N UONNBAGIVWWWEA-UHFFFAOYSA-N 0.000 claims description 2
- FGFYZZSIGNEZKF-UHFFFAOYSA-N 6-chloro-N-[2-fluoro-4-(pentafluoro-lambda6-sulfanyl)phenyl]-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide Chemical compound Fc1cc(ccc1NS(=O)(=O)c1c[nH]c2nc(Cl)ccc12)S(F)(F)(F)(F)F FGFYZZSIGNEZKF-UHFFFAOYSA-N 0.000 claims description 2
- ASMPQCUWEWQGDT-UHFFFAOYSA-N 6-chloro-N-[2-fluoro-4-(trifluoromethyl)phenyl]-1H-indole-3-sulfonamide Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C=C1)C(F)(F)F)F ASMPQCUWEWQGDT-UHFFFAOYSA-N 0.000 claims description 2
- JVKGSCDXSSZYGK-UHFFFAOYSA-N 7-chloro-N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-6-fluoro-1H-indole-3-sulfonamide Chemical compound ClC=1C(=CC=C2C(=CNC=12)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)OC)F JVKGSCDXSSZYGK-UHFFFAOYSA-N 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- WGNVQVKGTUKLGX-UHFFFAOYSA-N BrC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)CCCOC)F.C(#N)CC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=C1C=CC=1C=CC=NC21)F Chemical compound BrC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)CCCOC)F.C(#N)CC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=C1C=CC=1C=CC=NC21)F WGNVQVKGTUKLGX-UHFFFAOYSA-N 0.000 claims description 2
- NRPKGGWLJODCEC-UHFFFAOYSA-N C(#N)C1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C=1C(=NOC1C)C)F.ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=NC(=CC=C21)C2COC2)F Chemical compound C(#N)C1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C=1C(=NOC1C)C)F.ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=NC(=CC=C21)C2COC2)F NRPKGGWLJODCEC-UHFFFAOYSA-N 0.000 claims description 2
- WEHHIRADVNQJMY-UHFFFAOYSA-N C(#N)C1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C=1SC=CC1)F.ClC1=CC=C2C(=CNC2=C1OC)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)F Chemical compound C(#N)C1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C=1SC=CC1)F.ClC1=CC=C2C(=CNC2=C1OC)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)F WEHHIRADVNQJMY-UHFFFAOYSA-N 0.000 claims description 2
- YBQGRQPFHKKKGB-UHFFFAOYSA-N C(#N)C1=CC=C(C=C1)NS(=O)(=O)C1=CNC=2C=C3C(=CC12)OCO3.ClC3=CC(=C(C=C3)NS(=O)(=O)C3=CNC1=C3C=CC=3C=CC(=NC13)C(F)F)F Chemical compound C(#N)C1=CC=C(C=C1)NS(=O)(=O)C1=CNC=2C=C3C(=CC12)OCO3.ClC3=CC(=C(C=C3)NS(=O)(=O)C3=CNC1=C3C=CC=3C=CC(=NC13)C(F)F)F YBQGRQPFHKKKGB-UHFFFAOYSA-N 0.000 claims description 2
- QZBUWXLDYLECLC-UHFFFAOYSA-N ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C#N)F.BrC=1C=C(C(=NC1)NS(=O)(=O)C1=CNC2=NC(=CC=C21)Cl)OC Chemical compound ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C#N)F.BrC=1C=C(C(=NC1)NS(=O)(=O)C1=CNC2=NC(=CC=C21)Cl)OC QZBUWXLDYLECLC-UHFFFAOYSA-N 0.000 claims description 2
- RFLDOWMSEIFCFY-UHFFFAOYSA-N ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C(F)(F)F)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1C)I Chemical compound ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)C(F)(F)F)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1C)I RFLDOWMSEIFCFY-UHFFFAOYSA-N 0.000 claims description 2
- RDIBPQSOTKBVBU-UHFFFAOYSA-N ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=NC(=CC=C21)C2COCC2)F.FC2=C(C=C(C=C2)F)NS(=O)(=O)C2=CNC1=CC(=CC=C21)C Chemical compound ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=NC(=CC=C21)C2COCC2)F.FC2=C(C=C(C=C2)F)NS(=O)(=O)C2=CNC1=CC(=CC=C21)C RDIBPQSOTKBVBU-UHFFFAOYSA-N 0.000 claims description 2
- WQFSFERQWBHQSU-UHFFFAOYSA-N ClC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)OC)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1F)Cl Chemical compound ClC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)OC)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1F)Cl WQFSFERQWBHQSU-UHFFFAOYSA-N 0.000 claims description 2
- DQHJOWWZKZICGF-UHFFFAOYSA-N ClC1=CC2=C(C(=CO2)S(=O)(=O)NC2=C(C=C(C(=C2)F)OCC#N)F)C=C1.ClC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=C(C=C(C=C2)C(F)(F)F)F Chemical compound ClC1=CC2=C(C(=CO2)S(=O)(=O)NC2=C(C=C(C(=C2)F)OCC#N)F)C=C1.ClC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=C(C=C(C=C2)C(F)(F)F)F DQHJOWWZKZICGF-UHFFFAOYSA-N 0.000 claims description 2
- GQOUIZJXKATWBE-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C(=CC=C1)F)Cl.FC1=C(C=C(C=C1)F)NS(=O)(=O)C1=CNC2=NC=C(C=C21)I Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C(=CC=C1)F)Cl.FC1=C(C=C(C=C1)F)NS(=O)(=O)C1=CNC2=NC=C(C=C21)I GQOUIZJXKATWBE-UHFFFAOYSA-N 0.000 claims description 2
- JTGBHOGSCPCPPM-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C(=C1)F)OCC1CC1)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)OCCOC)F Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C(=C1)F)OCC1CC1)F.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)OCCOC)F JTGBHOGSCPCPPM-UHFFFAOYSA-N 0.000 claims description 2
- SOTCXJFVDQRVCS-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C=C1)CC#N)F.C(#N)CCC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=C1C=CC=1C=CC=NC21)F Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C=C1)CC#N)F.C(#N)CCC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=C1C=CC=1C=CC=NC21)F SOTCXJFVDQRVCS-UHFFFAOYSA-N 0.000 claims description 2
- MLZBVTVUVLFHOS-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=CC(=C1)F)C#N.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC2=C(COC2=O)C=C1 Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=CC(=C1)F)C#N.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC2=C(COC2=O)C=C1 MLZBVTVUVLFHOS-UHFFFAOYSA-N 0.000 claims description 2
- JNAHFBBYEPORFT-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=2C(=NON2)C=C1F.ClC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)S(=O)C)F Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=2C(=NON2)C=C1F.ClC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)S(=O)C)F JNAHFBBYEPORFT-UHFFFAOYSA-N 0.000 claims description 2
- CVXHKMAYFOUHFT-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=C(C2=NSN=C21)C#N.C(#N)C2=CC=C1C(=CNC1=C2)S(=O)(=O)NC2=CC1=C(OC(O1)(F)F)C=C2F Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=C(C2=NSN=C21)C#N.C(#N)C2=CC=C1C(=CNC1=C2)S(=O)(=O)NC2=CC1=C(OC(O1)(F)F)C=C2F CVXHKMAYFOUHFT-UHFFFAOYSA-N 0.000 claims description 2
- OOFNANGIMOLIDB-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=C(C=C1)C#N.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)C)F.N=1SN=C2C1C=CC=C2NS(=O)(=O)C2=CNC1=CC(=CC=C21)Cl Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=CC=C(C=C1)C#N.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)C)F.N=1SN=C2C1C=CC=C2NS(=O)(=O)C2=CNC1=CC(=CC=C21)Cl OOFNANGIMOLIDB-UHFFFAOYSA-N 0.000 claims description 2
- IDGUOZIKGQLNIB-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)C=C)F.BrC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=NC(=CC=C21)OC)F Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)C=C)F.BrC1=CC(=C(C=C1F)NS(=O)(=O)C1=CNC2=NC(=CC=C21)OC)F IDGUOZIKGQLNIB-UHFFFAOYSA-N 0.000 claims description 2
- NOHVITAFCHFACM-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)OC.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C(=C1)F)C#N)OC Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)OC.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=C(C=C(C(=C1)F)C#N)OC NOHVITAFCHFACM-UHFFFAOYSA-N 0.000 claims description 2
- RBBBUQQYGOVKSZ-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1F)COC.ClC=1C(=CC=C2C(=CNC12)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F)S(=O)C Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1F)COC.ClC=1C(=CC=C2C(=CNC12)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F)S(=O)C RBBBUQQYGOVKSZ-UHFFFAOYSA-N 0.000 claims description 2
- XOGDUOSRQRFTQD-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1OC)C(F)(F)F.BrC=1C=C(C(=NC1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)Cl)OC Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1OC)C(F)(F)F.BrC=1C=C(C(=NC1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)Cl)OC XOGDUOSRQRFTQD-UHFFFAOYSA-N 0.000 claims description 2
- CVRMHERUZUTUQZ-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1OC)OC.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C(=C1)OC)Cl Chemical compound ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C=C1OC)OC.ClC1=CC=C2C(=CNC2=C1)S(=O)(=O)NC1=NC=C(C(=C1)OC)Cl CVRMHERUZUTUQZ-UHFFFAOYSA-N 0.000 claims description 2
- NEDJZCHIVOMQPI-UHFFFAOYSA-N ClC1=CC=C2C(=CNC2=C1F)S(=O)(=O)NC1=NC(=C(C=C1F)CC#N)OC.ClC1=CC=C2C(=CNC2=C1OC)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)OC Chemical compound ClC1=CC=C2C(=CNC2=C1F)S(=O)(=O)NC1=NC(=C(C=C1F)CC#N)OC.ClC1=CC=C2C(=CNC2=C1OC)S(=O)(=O)NC1=NC(=C(C=C1F)Cl)OC NEDJZCHIVOMQPI-UHFFFAOYSA-N 0.000 claims description 2
- VJJLAZDDLBLLKL-UHFFFAOYSA-N ClC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=NC=C(C=C2F)C.ClC2=CC=C1C(=CNC1=C2)S(=O)(=O)NC2=C(C=C(C(=C2)F)OCC2=NC=CC=C2)F Chemical compound ClC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=NC=C(C=C2F)C.ClC2=CC=C1C(=CNC1=C2)S(=O)(=O)NC2=C(C=C(C(=C2)F)OCC2=NC=CC=C2)F VJJLAZDDLBLLKL-UHFFFAOYSA-N 0.000 claims description 2
- YLOUQABRHNPDKU-UHFFFAOYSA-N FC1(OC2=C(O1)C=C(C(=C2)NS(=O)(=O)C2=CNC1=C2C=CC=2C=CC=NC12)F)F.ClC1=CC=C2C(=CNC2=C1C=1C=NC=CC1)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F Chemical compound FC1(OC2=C(O1)C=C(C(=C2)NS(=O)(=O)C2=CNC1=C2C=CC=2C=CC=NC12)F)F.ClC1=CC=C2C(=CNC2=C1C=1C=NC=CC1)S(=O)(=O)NC1=C(C=C(C(=C1)F)Cl)F YLOUQABRHNPDKU-UHFFFAOYSA-N 0.000 claims description 2
- XBVSCWBAEQQBDG-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C)F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)S(=O)C.ClC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=NC(=C(C=C2F)C)F Chemical compound FC1=C(C=C(C(=C1)C)F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)S(=O)C.ClC1=CC=C2C(=N1)NC=C2S(=O)(=O)NC2=NC(=C(C=C2F)C)F XBVSCWBAEQQBDG-UHFFFAOYSA-N 0.000 claims description 2
- OZPGZCGQBCRCBS-UHFFFAOYSA-N N-(2,1,3-benzothiadiazol-4-yl)-5-iodo-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide Chemical compound N=1SN=C2C=1C=CC=C2NS(=O)(=O)C1=CNC2=NC=C(C=C21)I OZPGZCGQBCRCBS-UHFFFAOYSA-N 0.000 claims description 2
- TZRHCJMDAOLAOC-UHFFFAOYSA-N N-(2,1,3-benzothiadiazol-5-yl)-6-chloro-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide N-(4-ethynyl-2-fluorophenyl)-6-methoxy-1H-indole-3-sulfonamide Chemical compound Clc1ccc2c(c[nH]c2n1)S(=O)(=O)Nc1ccc2nsnc2c1.COc1ccc2c(c[nH]c2c1)S(=O)(=O)Nc1ccc(cc1F)C#C TZRHCJMDAOLAOC-UHFFFAOYSA-N 0.000 claims description 2
- DYFFHBIWVSPMEO-UHFFFAOYSA-N N-(4-chloro-2-fluorophenyl)-6-methoxy-1H-indole-3-sulfonamide Chemical compound ClC1=CC(=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)OC)F DYFFHBIWVSPMEO-UHFFFAOYSA-N 0.000 claims description 2
- JNABXWFWTCKFRB-UHFFFAOYSA-N N-(4-cyano-2-fluorophenyl)-6-(2,2,2-trifluoroethoxy)-1H-indole-3-sulfonamide N-(4-cyanophenyl)-6-methylsulfonyl-1H-indole-3-sulfonamide Chemical compound CS(=O)(=O)c1ccc2c(c[nH]c2c1)S(=O)(=O)Nc1ccc(cc1)C#N.Fc1cc(ccc1NS(=O)(=O)c1c[nH]c2cc(OCC(F)(F)F)ccc12)C#N JNABXWFWTCKFRB-UHFFFAOYSA-N 0.000 claims description 2
- PSOVHKGQDXFIGV-UHFFFAOYSA-N N-(4-cyano-2-fluorophenyl)-6-(cyclopropylmethoxy)-1H-indole-3-sulfonamide N-(4-ethynyl-2-fluorophenyl)-6-methoxy-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide Chemical compound COc1ccc2c(c[nH]c2n1)S(=O)(=O)Nc1ccc(cc1F)C#C.Fc1cc(ccc1NS(=O)(=O)c1c[nH]c2cc(OCC3CC3)ccc12)C#N PSOVHKGQDXFIGV-UHFFFAOYSA-N 0.000 claims description 2
- UXGOSWZKLUTXRJ-UHFFFAOYSA-N N-(4-ethynylphenyl)-6-methylsulfonyl-1H-indole-3-sulfonamide Chemical compound C(#C)C1=CC=C(C=C1)NS(=O)(=O)C1=CNC2=CC(=CC=C12)S(=O)(=O)C UXGOSWZKLUTXRJ-UHFFFAOYSA-N 0.000 claims description 2
- GCWPJZCLRQPMNC-UHFFFAOYSA-N N-(5-chloro-3-fluoro-6-methoxypyridin-2-yl)-6,7,8,9-tetrahydro-1H-benzo[g]indole-3-sulfonamide Chemical compound ClC=1C=C(C(=NC=1OC)NS(=O)(=O)C1=CNC2=C3C(=CC=C12)CCCC3)F GCWPJZCLRQPMNC-UHFFFAOYSA-N 0.000 claims description 2
- LDQBKDCVLDDGDF-UHFFFAOYSA-N N-(7-bromo-2,2-difluoro-1,3-benzodioxol-4-yl)-6-chloro-1H-indole-3-sulfonamide N-(4-cyano-2-fluorophenyl)-6-pyridin-4-yl-1H-indole-3-sulfonamide Chemical compound BrC1=CC=C(C2=C1OC(O2)(F)F)NS(=O)(=O)C2=CNC1=CC(=CC=C21)Cl.C(#N)C2=CC(=C(C=C2)NS(=O)(=O)C2=CNC1=CC(=CC=C21)C2=CC=NC=C2)F LDQBKDCVLDDGDF-UHFFFAOYSA-N 0.000 claims description 2
- PKTHFAINQJCQOO-UHFFFAOYSA-N N-[2-fluoro-4-(trifluoromethyl)phenyl]-6-methoxy-1H-indole-3-sulfonamide Chemical compound FC1=C(C=CC(=C1)C(F)(F)F)NS(=O)(=O)C1=CNC2=CC(=CC=C12)OC PKTHFAINQJCQOO-UHFFFAOYSA-N 0.000 claims description 2
- TVACXMSWYJXKLN-UHFFFAOYSA-N N=1SN=C2C1C=CC=C2NS(=O)(=O)C2=CNC1=CC(=CC=C21)OC.N=2SN=C1C2C=CC=C1NS(=O)(=O)C1=CNC2=C(C=CC=C12)Br Chemical compound N=1SN=C2C1C=CC=C2NS(=O)(=O)C2=CNC1=CC(=CC=C21)OC.N=2SN=C1C2C=CC=C1NS(=O)(=O)C1=CNC2=C(C=CC=C12)Br TVACXMSWYJXKLN-UHFFFAOYSA-N 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000003384 imaging method Methods 0.000 claims description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
- YSWBXDCVGOBVDQ-UHFFFAOYSA-N 5-methyl-N-phenyl-1-benzothiophene-3-sulfonamide Chemical compound CC1=CC2=C(C=C1)SC=C2S(=O)(=O)NC3=CC=CC=C3 YSWBXDCVGOBVDQ-UHFFFAOYSA-N 0.000 claims 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims 4
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 4
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
- 150000001349 alkyl fluorides Chemical class 0.000 claims 3
- 125000002346 iodo group Chemical group I* 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims 2
- MZJUGRUTVANEDW-UHFFFAOYSA-N bromine fluoride Chemical compound BrF MZJUGRUTVANEDW-UHFFFAOYSA-N 0.000 claims 2
- 150000002545 isoxazoles Chemical class 0.000 claims 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 claims 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 claims 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
- MGKPCLNUSDGXGT-UHFFFAOYSA-N 1-benzofuran-3-one Chemical compound C1=CC=C2C(=O)COC2=C1 MGKPCLNUSDGXGT-UHFFFAOYSA-N 0.000 claims 1
- NKPTVQFJWGCELJ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene 1,1-dioxide Chemical compound C1=CC=C2S(=O)(=O)CCC2=C1 NKPTVQFJWGCELJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 108010061951 Methemoglobin Proteins 0.000 claims 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical group CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000006215 cyanomethylation reaction Methods 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000006006 difluoroethoxy group Chemical group 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 210000002816 gill Anatomy 0.000 claims 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
- 101000829770 Homo sapiens Uracil nucleotide/cysteinyl leukotriene receptor Proteins 0.000 description 22
- 102100023407 Uracil nucleotide/cysteinyl leukotriene receptor Human genes 0.000 description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 21
- 125000006563 (C1-3) alkylaminocarbonyl group Chemical group 0.000 description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 5
- 125000005553 heteroaryloxy group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 description 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 3
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 3
- AYTPIVIDHMVGSX-UHFFFAOYSA-N 2,1,3-benzoselenadiazole Chemical compound C1=CC=CC2=N[se]N=C21 AYTPIVIDHMVGSX-UHFFFAOYSA-N 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 125000006597 (C1-C3) alkylcarbonylamino group Chemical group 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- GWNPPHYEJITOHT-UHFFFAOYSA-N methanesulfinyl fluoride Chemical compound CS(F)=O GWNPPHYEJITOHT-UHFFFAOYSA-N 0.000 description 2
- KNWQLFOXPQZGPX-UHFFFAOYSA-N methanesulfonyl fluoride Chemical compound CS(F)(=O)=O KNWQLFOXPQZGPX-UHFFFAOYSA-N 0.000 description 2
- 210000005012 myelin Anatomy 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000006560 (C1-C5)alkylcarbonylamino group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- KVRZARWOKBNZMM-UHFFFAOYSA-N 1,3-dihydro-2-benzothiophene Chemical group C1=CC=C2CSCC2=C1 KVRZARWOKBNZMM-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 description 1
- WMNOGEJVPQWZON-UHFFFAOYSA-N azidooxycyclopropane Chemical compound C1(CC1)ON=[N+]=[N-] WMNOGEJVPQWZON-UHFFFAOYSA-N 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical group [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021150157A JP7270011B2 (ja) | 2016-12-28 | 2021-09-15 | （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16207137.7 | 2016-12-28 | ||
| EP16207137 | 2016-12-28 | ||
| PCT/EP2017/084602 WO2018122232A1 (en) | 2016-12-28 | 2017-12-27 | (aza)indole-, benzothiophene-, and benzofuran-3-sulfonamides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021150157A Division JP7270011B2 (ja) | 2016-12-28 | 2021-09-15 | （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504753A JP2020504753A (ja) | 2020-02-13 |
| JP2020504753A5 true JP2020504753A5 (enExample) | 2020-04-02 |
| JP6946436B2 JP6946436B2 (ja) | 2021-10-06 |
Family
ID=57614285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535368A Active JP6946436B2 (ja) | 2016-12-28 | 2017-12-27 | （アザ）インドール−、ベンゾチオフェン−、及びベンゾフラン−３−スルホンアミド |
| JP2021150157A Active JP7270011B2 (ja) | 2016-12-28 | 2021-09-15 | （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021150157A Active JP7270011B2 (ja) | 2016-12-28 | 2021-09-15 | （アザ）インドール－、ベンゾチオフェン－、及びベンゾフラン－３－スルホンアミド |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US11345662B2 (enExample) |
| EP (1) | EP3562820A1 (enExample) |
| JP (2) | JP6946436B2 (enExample) |
| KR (1) | KR102537100B1 (enExample) |
| CN (3) | CN116283712B (enExample) |
| AR (1) | AR110592A1 (enExample) |
| AU (2) | AU2017387695B2 (enExample) |
| CA (1) | CA3045244A1 (enExample) |
| CL (1) | CL2019001660A1 (enExample) |
| CO (1) | CO2019007829A2 (enExample) |
| CR (1) | CR20190287A (enExample) |
| EA (1) | EA201991553A1 (enExample) |
| EC (1) | ECSP19044183A (enExample) |
| IL (2) | IL295047B2 (enExample) |
| MX (1) | MX2019006190A (enExample) |
| MY (1) | MY199872A (enExample) |
| NZ (1) | NZ753651A (enExample) |
| PE (1) | PE20191475A1 (enExample) |
| PH (1) | PH12019501095A1 (enExample) |
| RU (1) | RU2767904C2 (enExample) |
| TN (1) | TN2019000165A1 (enExample) |
| TW (1) | TWI754702B (enExample) |
| UA (1) | UA127890C2 (enExample) |
| UY (1) | UY37554A (enExample) |
| WO (1) | WO2018122232A1 (enExample) |
| ZA (1) | ZA201903466B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
| MX2020011050A (es) * | 2018-04-20 | 2021-03-09 | Virginia Tech Intellectual Properties Inc | Imidazopiridinas útiles como desacopladores mitocondriales. |
| TWI857957B (zh) * | 2018-06-19 | 2024-10-11 | 德商Ｕｃｂ製藥有限公司 | 吡啶基及吡基-（氮）吲哚磺醯胺 |
| EP3584244A1 (en) * | 2018-06-20 | 2019-12-25 | UCB Pharma GmbH | Substituted alkoxypyridinyl indolsulfonamides |
| TW202024023A (zh) * | 2018-09-03 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| CN110128422B (zh) * | 2019-01-04 | 2022-03-18 | 金凯(辽宁)生命科技股份有限公司 | 5-甲氧基-7-氮杂吲哚的合成方法 |
| WO2020150439A1 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| GB201903671D0 (en) * | 2019-03-18 | 2019-05-01 | Univ Edinburgh | Small molecule photosensitizers for photodynamic therapy |
| US12358875B2 (en) * | 2019-06-17 | 2025-07-15 | Ucb Pharma Gmbh | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis |
| EP4143303A4 (en) * | 2020-05-01 | 2024-09-04 | The Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR PROMOTING MYELINIZATION |
| CN112375027B (zh) * | 2020-12-07 | 2023-03-31 | 中国药科大学 | 吲哚磺酰胺类衍生物及其医药用途 |
| CN112266328B (zh) * | 2020-12-09 | 2023-11-03 | 郑州萃智医药科技有限公司 | 3-氟-4-硝基苯甲醛的合成路线及制备方法 |
| AU2022227183A1 (en) * | 2021-02-26 | 2023-06-22 | F. Hoffmann-La Roche Ag | Novel pyrimidin-2-yl sulfonamide derivatives |
| TW202313569A (zh) * | 2021-06-04 | 2023-04-01 | 比利時商理溫醫療公司 | 吡咯基磺胺化合物 |
| TW202317087A (zh) | 2021-08-10 | 2023-05-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關病況之化合物及組合物 |
| CN114276319B (zh) * | 2022-01-06 | 2023-11-03 | 滁州学院 | 一种劳拉替尼中间体的合成方法 |
| CN114315741B (zh) * | 2022-01-19 | 2023-09-12 | 贵州医科大学 | 一种硫代化合物及其制备方法与应用 |
| JP2025523939A (ja) | 2022-07-20 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | 新規のナフチルおよびイソキノリンスルホンアミド誘導体 |
| WO2024017855A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds |
| WO2024017856A1 (en) | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives |
| WO2024017857A1 (en) * | 2022-07-20 | 2024-01-25 | F. Hoffmann-La Roche Ag | Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives |
| JP2025523899A (ja) | 2022-07-20 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | 新規ピリミジニルおよびトリアジニルスルホンアミド誘導体 |
| AU2023380534A1 (en) * | 2022-11-20 | 2025-05-22 | Myrobalan Therapeutics, Inc. | Gpr17 modulators and uses thereof |
| WO2024115733A1 (en) * | 2022-12-02 | 2024-06-06 | Rewind Therapeutics Nv | Fused pyrrolyl-sulfonamide compounds |
| WO2024153233A1 (en) * | 2023-01-19 | 2024-07-25 | Nanjing Immunophage Biotech Co., Ltd | Compounds and their uses as gpr17 antagonists |
| CN116947879B (zh) * | 2023-07-25 | 2025-10-31 | 沈阳药科大学 | 一种bbi608类衍生物及其制备方法和在制备治疗stat3介导疾病的药物中的应用 |
| TW202515863A (zh) * | 2023-08-15 | 2025-04-16 | 美商百健Ｍａ公司 | 作為ｇｐｒ１７調節劑之吲哚及吡咯并吡啶衍生物 |
| WO2025195241A1 (zh) * | 2024-03-19 | 2025-09-25 | 迈巴制药(南京)有限公司 | Gpr17受体抑制剂及其用途 |
| WO2025243044A1 (en) | 2024-05-23 | 2025-11-27 | Pheno Therapeutics Limited | Compounds |
| GB2700773A (en) | 2024-05-23 | 2026-03-11 | Pheno Therapeutics Ltd | Compounds |
| GB2642355A (en) * | 2024-07-05 | 2026-01-07 | Pheno Therapeutics Ltd | Polymorphs |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| EP1159263A1 (en) * | 1999-02-26 | 2001-12-05 | Merck & Co., Inc. | Novel sulfonamide compounds and uses thereof |
| US6521658B1 (en) * | 1999-05-28 | 2003-02-18 | Abbott Laboratories | Cell proliferation inhibitors |
| SE9904750D0 (sv) | 1999-12-23 | 1999-12-23 | Pharmacia & Upjohn Ab | New formulation, use and method |
| NZ528450A (en) * | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
| SE0102048D0 (sv) * | 2001-06-11 | 2001-06-11 | Pharmacia Ab | New Compounds |
| WO2005103291A1 (ja) | 2004-04-27 | 2005-11-03 | Takeda Pharmaceutical Company Limited | Ｇタンパク質共役型レセプタータンパク質の新規リガンドとその用途 |
| ITMI20042007A1 (it) | 2004-10-21 | 2005-01-21 | Consiglio Nazionale Ricerche | "modulatori del ricettore gpr17 e loro impieghi terapeutici" |
| DE112008002309A5 (de) | 2007-06-25 | 2010-05-27 | Acino Ag | Elektrophoretisches transdermales Applikationssystem |
| WO2009080223A1 (en) * | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Cyclic pyridyl-n-(1,3,4)-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| US8318725B2 (en) * | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
| WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| US20110220151A1 (en) | 2010-03-11 | 2011-09-15 | Swinford Jerry L | Method and Apparatus for Washing Downhole Tubulars and Equipment |
| EP2567698B1 (en) * | 2011-09-07 | 2014-02-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | GPR 17 agonists and screening assay |
| KR20150008468A (ko) | 2012-05-09 | 2015-01-22 | 폰다지오네 이탈리아나 스클레로시 멀티플라 - 에프아이에스엠 온러스 | Gpr17 수용체 조절제 |
| RU2519546C1 (ru) * | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| EP2998294A1 (en) * | 2014-09-16 | 2016-03-23 | Sanofi | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| EP2997966A1 (en) * | 2014-09-16 | 2016-03-23 | Sanofi | Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders |
| WO2016089062A2 (en) * | 2014-12-02 | 2016-06-09 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| ES2856125T3 (es) * | 2016-02-05 | 2021-09-27 | Ea Pharma Co Ltd | Derivado de sulfonamida y composición farmacéutica que contiene la misma |
| TWI754702B (zh) | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
-
2017
- 2017-11-29 TW TW106141591A patent/TWI754702B/zh active
- 2017-12-27 IL IL295047A patent/IL295047B2/en unknown
- 2017-12-27 TN TNP/2019/000165A patent/TN2019000165A1/en unknown
- 2017-12-27 NZ NZ753651A patent/NZ753651A/en unknown
- 2017-12-27 CN CN202211685410.5A patent/CN116283712B/zh active Active
- 2017-12-27 US US16/474,245 patent/US11345662B2/en active Active
- 2017-12-27 RU RU2019123031A patent/RU2767904C2/ru active
- 2017-12-27 EA EA201991553A patent/EA201991553A1/ru unknown
- 2017-12-27 UA UAA201905854A patent/UA127890C2/uk unknown
- 2017-12-27 CR CR20190287A patent/CR20190287A/es unknown
- 2017-12-27 KR KR1020197022003A patent/KR102537100B1/ko active Active
- 2017-12-27 AU AU2017387695A patent/AU2017387695B2/en active Active
- 2017-12-27 WO PCT/EP2017/084602 patent/WO2018122232A1/en not_active Ceased
- 2017-12-27 AR ARP170103687A patent/AR110592A1/es unknown
- 2017-12-27 CN CN202211685552.1A patent/CN116036078B/zh active Active
- 2017-12-27 CA CA3045244A patent/CA3045244A1/en active Pending
- 2017-12-27 EP EP17835855.2A patent/EP3562820A1/en active Pending
- 2017-12-27 CN CN201780081379.5A patent/CN110121499B/zh active Active
- 2017-12-27 MY MYPI2019003712A patent/MY199872A/en unknown
- 2017-12-27 PE PE2019001334A patent/PE20191475A1/es unknown
- 2017-12-27 JP JP2019535368A patent/JP6946436B2/ja active Active
- 2017-12-27 MX MX2019006190A patent/MX2019006190A/es unknown
- 2017-12-28 UY UY0001037554A patent/UY37554A/es not_active Application Discontinuation
-
2019
- 2019-05-16 PH PH12019501095A patent/PH12019501095A1/en unknown
- 2019-05-31 ZA ZA2019/03466A patent/ZA201903466B/en unknown
- 2019-06-17 IL IL267438A patent/IL267438B2/en unknown
- 2019-06-17 CL CL2019001660A patent/CL2019001660A1/es unknown
- 2019-06-20 EC ECSENADI201944183A patent/ECSP19044183A/es unknown
- 2019-07-22 CO CONC2019/0007829A patent/CO2019007829A2/es unknown
-
2021
- 2021-09-15 JP JP2021150157A patent/JP7270011B2/ja active Active
- 2021-10-20 US US17/506,331 patent/US12071404B2/en active Active
-
2022
- 2022-01-05 US US17/568,824 patent/US11820746B2/en active Active
- 2022-09-21 AU AU2022235580A patent/AU2022235580B2/en active Active
-
2023
- 2023-07-07 US US18/219,417 patent/US20230348384A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504753A5 (enExample) | ||
| RU2019123031A (ru) | (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды | |
| US11124486B2 (en) | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | |
| KR102399891B1 (ko) | 항암 및 항-증식 활성을 나타내는 2-아미노피리미딘-6-온 및 유사체 | |
| KR102626982B1 (ko) | Pge2 수용체 조절제로서의 피리미딘 유도체 | |
| RU2681849C2 (ru) | Гетероциклические производные и их применение | |
| RU2733750C2 (ru) | Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение | |
| WO2007143597A2 (en) | Organic compounds | |
| CN110267954B (zh) | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 | |
| WO2016006706A1 (ja) | テトラヒドロピラ二ルメチル基を有するピリドン誘導体 | |
| TWI329013B (en) | Cannabinoid receptor modulator | |
| US11685740B2 (en) | Bicyclic nitrogen-containing heterocyclic derivatives and pharmaceutical composition comprising the same | |
| US11471436B2 (en) | Dihydronaphthalene derivative | |
| AR074129A1 (es) | Inhibidores de la diacilglicerolaciltransferasa | |
| US20240299385A1 (en) | 3-pyrrolylsulfonamide compounds as gpr17 antagonists | |
| WO2017192304A1 (en) | Arylcarboxamides and uses thereof | |
| KR101589837B1 (ko) | 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도 | |
| TH1901004016A (th) | (อะซา)อินโดล-, เบนโซไธโอฟีน-, และเบนโซฟูแรน-3-ซัลโฟนาไมด์ | |
| BR112019006675B1 (pt) | Derivado heterocíclico nitrogenado bicíclico, composição farmacêutica compreendendo o mesmo e seus usos |